[Prevention of restenosis and of cardiac events after coronary angioplasty in diabetics] Revue médicale suisse [Rev Med Suisse] Journal article

Title	[Prevention of restenosis and of cardiac events after coronary angioplasty in diabetics]
Author(s)	Nyssen A, Legrand V, Scheen AJ
Institution	Université de Liège, Service de diabétologie, nutrition et maladies métaboliques et Unité de pharmacologie clinique, Département de médecine, CHU Sart Tilman, 4000 Liège, Belgique.
Source	Rev Med Suisse 2009 Aug 26; 5(214):1638-43.
MeSH	Angioplasty, Transluminal, Percutaneous Coronary Angiotensin II Type 1 Receptor Blockers Anti-Inflammatory Agents Antioxidants Belgium Coronary Restenosis Coronary Thrombosis Diabetes Complications Diabetes Mellitus, Type 2 Drug Therapy, Combination Drug-Eluting Stents Fatty Acids, Omega-3 Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Hypoglycemic Agents Immunologic Factors Incidence Meta-Analysis as Topic Platelet Aggregation Inhibitors Risk Factors Treatment Outcome
Abstract	Various systemic pharmacological approaches have been evaluated to reduce the risk of restenosis and clinical complications after coronary angioplasty, with or without stent, a main objective in the high risk diabetic population. The aim of the present paper is to describe the effects of the main pharmacological classes on the risk of restenosis, the need for new revascularisation procedures and the incidence of major clinical events (MACE: death, myocardial infarction, revascularisation). We will analyse successively the role of antiplatelet agents, omega 3 fatty acids, statins, anti-inflammatory compounds, immunomodulators, anti-oxidants and inhibitors of the renin-angiotensin system. Whenever possible, we will focus our attention on the results obtained in the diabetic population.
Language	fre
Pub Type(s)	English Abstract Journal Article Review
PubMed ID	19772194